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Abstract
Background/Aim: Patients with idiopathic focal segmen-
tal glomerulosclerosis (FSGS) often develop a recur-
rence of the disease after kidney transplantation. In a
number of FSGS patients, plasmapheresis and immu-
noadsorption procedures have been shown to tran-
siently reduce proteinuria and are thought to do this by
eliminating a circulating factor. Direct cellular effects of
eluates from immunoadsorption procedures on podo-
cytes, the primary target of injury in FSGS, have not yet
been reported. Methods: Eluates were derived from anti-
body-based immunoadsorption of a patient suffering
from primary FSGS, a patient with systemic lupus ery-
thematosus, and a healthy volunteer. The cytosolic free
Ca2+ concentration ([Ca2+]i) of differentiated podocytes
was measured by single-cell fura-2 microfluorescence
measurements. Free and total immunoreactive kinin lev-
els were measured by radioimmunoassay. Results:
FSGS eluates increased the [Ca2+]i levels concentration
dependently (EC50 0.14 mg/ml; n = 3–19). 1 mg/ml eluate
increased the [Ca2+]i values reversibly from 82 B 12 to
1,462 B 370 nmol/l, and then they returned back to 100
B 16 nmol/l (n = 19). The eluate-induced increase of
[Ca2+]i consisted of an initial Ca2+ peak followed by a Ca2+
plateau which depended on the extracellular Ca2+ con-
centration. The eluate-induced increase of [Ca2+]i was
inhibited by the specific B2 kinin receptor antagonist
Hoe 140 in a concentration-dependent manner (IC50
2.47 nmol/l). In addition, prior repetitive application of
bradykinin desensitized the effect of eluate on [Ca2+]i. A
colonic epithelial cell line not reacting to bradykinin did
not respond to eluate either (n = 6). Similar to FSGS
eluates, the eluate preparations of both the systemic
lupus patient and the healthy volunteer led to a biphasic,
concentration-dependent [Ca2+]i increase in podocytes
which again was inhibited by Hoe 140. Free kinins were
detected in all eluate preparations. Conclusion: The pro-
cedure of antibody-based immunoadsorption leads to ki-
nin in the eluate which elevates the [Ca2+]i level of podo-
cytes via B2 kinin receptors.
Copyright © 2002 S. Karger AG, Basel
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Introduction
At present, the pathogenesis of idiopathic focal seg-
mental glomerulosclerosis (FSGS) is undefined. A num-
ber of observations led to the assumption that a circulat-
ing factor or circulating factors might cause the disease:
(1) up to 40% of the FSGS patients develop a recurrence
of the disease early after kidney transplantation [1]; (2)
infants of mothers with therapy-resistant FSGS show a
transient nephrotic syndrome directly after delivery [2];
(3) injection of plasma of FSGS patients induces protein-
uria in rats [3]; and (4) plasmapheresis of FSGS patients
ameliorates proteinuria [4]. Dantal et al. [5] demonstrated
that protein adsorption by protein A Sepharose columns
reduced the urinary protein excretion of patients with
FSGS and, in addition, that the respective eluates caused
albuminuria in rats. Later on, Savin et al. [6] showed that
FSGS patient serum, but not serum from patients suffer-
ing from other glomerular diseases, led to an increased
albumin permeability of glomeruli in vitro. Recently, the
eluate activity putatively responsible for this effect was
further characterized and called ‘the FSGS factor’ [7].
With regard to plasma factors putatively involved in the
pathogenesis of FSGS, recent reports focused on serum
components capable of inhibiting the plasma permeabili-
ty [8, 9]. Here, it was suggested that an imbalance between
permeability factors and their inhibitors due either to
increased production and/or urinary loss may constitute a
central event in FSGS [10].
Despite all these findings, the exact nature of the circu-
lating factor thought to induce FSGS has not yet been
defined. Moreover, Esnault et al. [11] showed that immu-
noadsorption (IA) also efficiently reduced proteinuria
caused by a number of other diseases: membranous
nephropathy, diabetes mellitus, IgA nephropathy, and
amyloidosis. Based on their data, these authors suggested
that IA removes a nonspecific circulating hemodynamics-
altering or permeability-increasing factor.
The target of the circulating factor postulated to cause
FSGS is not known at present. Recent studies focused on
the role of podocyte damage in the development of glo-
merular sclerosis in general [12]. Furthermore, the podo-
cyte was defined as primary target of injury in FSGS [13].
Owing to the lack of a reliable model to study the podo-
cyte physiology in vitro, up to now no data are available
addressing possible mechanisms of podocyte damage in
FSGS. Recently, mouse podocyte cell clones have been
established, expressing specific proteins of differentiated,
nonproliferating podocytes [14], such as the Wilms’ tu-
mor gene product WT-1 located in the nucleus [15] or the
protein synaptopodin located in the foot processes [16].
Podocytes in culture thus provide a promising tool to
investigate a potential direct cellular alteration by the
putative FSGS-causing factor(s).
In the present study, we investigated the effect of
eluates from antibody-based IA procedures on the free
cytosolic Ca2+ concentration of differentiated podocytes.
Subjects and Methods
Patient with Primary FSGS
The male patient suffered from nephrotic syndrome due to biop-
sy-proven FSGS which led to end-stage renal insufficiency. Shortly
after a cadaveric kidney transplantation, the patient developed
nephrotic syndrome again. A kidney transplant biopsy again showed
FSGS which subsequently led to graft loss. After a second kidney
transplantation, consisting of pediatric en bloc kidneys localized
intra-abdominally, the patient first demonstrated a good transplant
function. However, shortly after, nephrotic syndrome occurred again
accompanied by a deterioration of the excretory kidney function
which was most likely due to recurrent FSGS also in the second trans-
plant. As all medical treatment with diverse immunosuppressive
agents (steroids, chlorambucil, cyclophosphamide, ciclosporin A) did
not improve the clinical course, after written consent an antibody-
based IA therapy was begun using antihuman IgG cartridges. During
the course of this treatment, the renal function improved, and pro-
teinuria declined by more than 50%. During IA, medication did not
include an angiotensin-converting enzyme (ACE) inhibitor. Eluate
derived by IA from this patient increased the albumin permeability
of the glomeruli in the test system described by Savin et al. [17].
Patient with Systemic Lupus Erythematosus (SLE)
The female patient suffered from SLE associated with lupus
nephritis, leading to end-stage renal insufficiency. Six years after
renal transplantation, SLE flared up (antinuclear antibody titer
1:1,600) despite immunosuppression. Upon deterioration of the
renal function, transplant biopsy showed recurrent lupus nephritis in
combination with acute rejection. As all subsequent medical treat-
ments with diverse immunosuppressives did not improve her clinical
course, after written consent antibody-based IA therapy was begun,
using antihuman IgG cartridges.
Healthy Volunteer
After written consent, the healthy male individual from the medi-
cal staff of the Department of Nephrology underwent a single anti-
body-based IA treatment, using antihuman IgG cartridges. Three
apheresis cycles were performed, as described below.
Extracorporeal Antibody-Based IA
Blood was drawn from a Cimino shunt or large (ante)cubital veins
via a dialysis needle (15 gauges; Bionic, Friedrichsdorf, Germany) at
a flow rate of 100–120 ml/min. Heparin was added for anticoagula-
tion (1,000 U/h). Plasma separation was performed with a miro-sorb
system (Baxter, Unterschleissheim, Germany) and a hollow-fiber
plasmapheresis filter (polypropylene; Hemaplex BT 900, 0.4 m2;
Dideco, Mirandola, Italy). Removal of immunoglobulins was accom-
plished with two sterile and pyrogen-free columns, each containing
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polyclonal sheep antibodies against human immunoglobulin (IgG,
IgA, and IgM) heavy and light chains conjugated to cyanogen bro-
mide activated Sepharose CL-4B beads (Ig-Therasorb, Baxter). Each
column had an immunoglobulin-binding capacity of approximately
4.0 g. In each apheresis cycle lasting 15 min, 250 ml of plasma was
loaded on one column (plasma flow 50–60 ml/min), while the other
column was regenerated, followed by the same procedure using the
second column (total plasma volume/cycle: 500 ml). 10–14 cycles
were performed within one IA session lasting 2.5–3.5 h. Therefore, a
total of 5–7 liters plasma passed the columns in each session. The
columns were regenerated by protein elution with glycine buffer at
pH 2.8, followed by washing cycles with phosphate-buffered saline
and 9 g/l isotonic sodium chloride solution, pH 7.4. The miro-sorb
system allowed for automated control of plasma fluid and regenera-
tion of solutions in the IA columns. After passing the IA columns,
patient plasma and separated blood cells were reinfused into the
patient either through the shunt or a contralateral (ante)cubital vein.
Each pair of reusable columns was assigned to 1 single patient. Col-
umns were kept filled with storage buffer (phosphate-buffered saline,
0.01% sodium azide, pH 7.2) at 10°C between the IA sessions.
Preparation of Eluates for in vitro Experiments
Each eluate portion was filled in a modified cellulose tubing and
dialyzed for 48 h at 8°C against bidistilled water. Thereafter, eluates
were lyophilized and stored at –40 °C until use. For use, the lyophi-
lisates were resuspended in a Ringer-like solution.
Generation and Culturing of Podocyte Cell Lines
The culturing of podocyte cell lines has been described in detail
previously [18]. Immortalized mouse podocytes were derived from
mice that have a thermosensitive variant of the SV40-T antigen
inserted into the mouse genome. These mouse podocytes proliferate
at 33°C and in the presence of interferon gamma (SV40-T antigen
active). At 37°C and after removal of interferon gamma, the cells
transform into the quiescent, differentiated phenotype [18]. Within
the current study, the cells stained positive for the podocyte markers
WT-1 [15], synaptopodin [19], nephrin [20], and p57 [21]. In addi-
tion, mRNA expression of the podocyte marker CD2AP [22] was
detected by RT-PCR. For experiments, cells between passages 15
and 25 were seeded at 37 °C into six-well plates and cultured in stan-
dard RPMI media containing 1% fetal calf serum (Boehringer Mann-
heim, Germany) and 100 U/ml penicillin and 100 mg/ml streptomy-
cin (both Gibco, Eggenstein, Germany) for at least 14 days, until the
cells were differentiated, showing an arborized morphology.
Culturing of Human Colonic Epithelial Cells
The human colonic epithelial cell line HT29 was kindly provided
by Prof. R. Greger, Department of Physiology, University of Frei-
burg, Germany. Its culturing was performed as recently described
[23].
Measurements of the Free Intracellular Calcium Concentration
([Ca2+]i)
Measurements of [Ca2+]i with the Ca2+-sensitive fluorescent dye
fura-2/AM (5 ÌM; Molecular Probes, Portland, Oreg., USA) were
performed in single podocytes with an inverted fluorescence micro-
scope setup in a modified version from that recently described in
detail [24]. In brief, the light from a 75-watt xenon lamp (Osram,
Köln, Germany) was directed through a tempax filter to avoid ther-
mal damage of the three excitation filters (Lys and Optiks, Lyngby,
Denmark) mounted on a motor-driven filter wheel (10 cycles/s). The
excitation filters were 10-nm bandpass filters with transmission max-
ima at 340, 360, and 380 nm. A dichroic mirror (FT425; Zeiss, Ober-
kochen, Germany) and a bandpass filter (500–530 nm, Lys and
Optiks) were used in the emission light pass. The fluorescence field of
a phototube (Hamamatsu H3460, Herrsching, Germany) could be
chosen by means of an adjustable rectangular diaphragm (50–150 !
30 Ìm). After amplification, the photocurrent of the photocounter
was digitized with a 12-bit A/D converter (MPC 64, Zeiss) and
recorded continuously by means of a personal computer. The fluores-
cence values for the three excitation wavelengths for each turn of the
wheel were computed. In 20 experiments, the calibration of the fura-
2 fluorescence signal could be successfully performed at the end of
the protocol, using the Ca2+ ionophore ionomycin (5 Ìmol/l) and low-
and high-Ca2+ buffers, as described previously in detail [24]. [Ca2+]i
was calculated according to the equation described by Grynkiewicz
et al. [25]. A KD for the fura-2-Ca2+ complex of 224 nmol/l (37 °C)
was assumed. The given concentrations for the Ca2+ peak refer to the
highest magnitude of the fluorescence ratio. Data are mainly given as
fluorescence ratio 340/380 nm.
Determination of Free and Total Immunoreactive Kinin
Lyophilized eluate was dissolved in deionized water; insoluble
material was removed by centrifugation for 5 min at 10,000 g. Con-
centrations of free and total immunoreactive kinins in these solutions
were determined analogously to a method described previously [26].
In brief: For determination of free kinin, 0.4 ml of the solution was
mixed with 1.6 ml absolute ethanol, the precipitate was removed by
centrifugation, and the supernatant was evaporated to dryness. For
determination of total kinin, an aliquot of the solution was incubated
with trypsin before ethanolic extraction. The dry residue was dis-
solved in radioimmunoassay buffer, and the kinin concentration was
determined by a radioimmunoassay using antibodies specific for kin-
ins [27]. In a second set of experiments, determination of the kinin
concentrations was performed after lyophilized eluate was dissolved
in a Ringer-like solution supplemented with 2 mmol/l EDTA (final
eluate concentration 1 mg/ml). In a third set of experiments, podo-
cytes were incubated with lyophilized eluate dissolved in a Ringer-
like solution (0.2 ml, final eluate concentration 1 mg/ml) for 4 or
40 min. In a fourth set of experiments, podocytes were incubated with
lyophilized eluate dissolved in a Ringer-like solution supplemented
with 2 mmol/l EDTA (final eluate concentration 1 mg/ml) for the
same time periods. In each series, supernatants then were removed
and mixed with 1.6 ml absolute ethanol. The preparation of the dif-
ferent samples for kinin measurements was performed as described
above. EDTA was added in the second and fourth set of experiments
in order to inhibit kininases which might be present in the eluate, on
the outer cell membrane, or be released from podocytes.
Chemicals
Chemicals were of the highest grade of purity available and were
obtained from Sigma unless otherwise indicated.
Statistics
The data are presented as mean values B SEM (n), where n refers
to the number of experiments. A paired t test was used to compare
mean values within one experimental series. p ^ 0.05 was accepted
to indicate statistical significance. Concentration-response curves
were calculated by nonlinear regression analysis using the Hill formu-
la with four parameters.
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Fig. 1. Eluate derived by IA from a patient
suffering from recurrent FSGS elevates the
[Ca2+]i of differentiated podocytes. A Origi-
nal recording of the [Ca2+]i response of a sin-
gle differentiated podocyte to increasing
concentrations of FSGS eluate. B Concentra-
tion-response curves of different eluate frac-
tions collected either shortly after the start
(fraction 2, EC50 0.14 mg/ml) or in the mid-
dle (fraction 7, EC50 0.13 mg/ml) of the same
IA session, respectively. FR = Fluorescence
ratio.
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Results
Eluate Derived by IA from an FSGS Patient Elevates
the [Ca2+]i in Differentiated Podocytes
Eluate derived by antibody-based IA from a FSGS
patient increased the [Ca2+]i of differentiated mouse
podocytes in a rapid and reversible manner (fig. 1A). This
effect was concentration-dependent with an EC50 of
0.14 mg/ml (n = 3–19, fig. 1B). 1 mg/ml eluate increased
the [Ca2+]i reversibly from 82 B 12 to 1,462 B 370 nmol/l
which returned back to 100 B 16 nmol/l (n = 19). This
eluate-induced increase of [Ca2+]i consisted of an initial
Ca2+ peak mainly due to release of Ca2+ from intracellular
Ca2+ stores followed by a Ca2+ plateau which depended on
extracellular Ca2+ (fig. 2A, B; n = 8). As compared with
the first eluate fraction, the effect of an eluate fraction col-
lected before the end of the same IA session (fraction
No. 7) on [Ca2+]i was slightly diminished (cf. fig. 1A).
Eluate derived from a session rinsing blood and plasma
compartment with a Ringer solution did not elevate
[Ca2+]i levels of podocytes (data not shown). Nicardipine,
a blocker of L-type Ca2+ channels, was without effect on
the initial Ca2+ spike and the sustained Ca2+ plateau
(fig. 2A, C; n = 5).
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Fig. 2. The FSGS eluate induced Ca2+ tran-
sient is biphasic with an initial Ca2+ peak,
followed by a Ca2+ plateau, which is depen-
dent on extracellular Ca2+. A Original re-
cording of the effects of a reduced extracellu-
lar Ca2+ (from 1 mmol/l to 1 Ìmol/l; Ca2+↓)
and of nicardipine (Nica; 1 Ìmol/l) on the
eluate-induced Ca2+ transient (eluate =
1 mg/ml; E). B Summary of the data (elu-
ate = 1 mg/ml, E; n = 8; * p ! 0.05). The L-
type Ca2+ channel blocker nicardipine does
not block the FSGS eluate induced trans-
membrane Ca2+ influx. C Summary of the
effect of nicardipine (Nica; 1 Ìmol/l) on the
eluate-induced Ca2+ transient (eluate = 1 mg/
ml, E; n = 5). FR = Fluorescence ratio; plat. =
plateau.
0
1
2
3
4
5
6
FR
 3
40
/3
80
 n
m
Ca
E E E
2+
Peak Plat.
*
Peak Plat. Peak Plat.
n = 8
0
1
2
3
4
5
6
7
FR
 3
40
/3
80
 n
m
Nica
E E E
Peak Plat.
*
Peak Plat. Peak Plat.
n = 5
0
1
2
3
4
5
6
7
FR
 3
40
/3
80
 n
m
5 min
E EE E
Nica Ca 2+
A
B C
Fig. 3. Repeated application of bradykinin
(100 nmol/l; BK) desensitizes the Ca2+ re-
sponse of podocytes to FSGS eluate (1 mg/
ml; E). Original recording (n = 5). The re-
sponse to ATP (100 Ìmol/l) is not affected.
FR = Fluorescence ratio.
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Fig. 4. The FSGS eluate induced Ca2+ tran-
sient of podocytes is blocked by the specific
B2 kinin receptor antagonist Hoe 140.
A Original recording (eluate = 1 mg/ml, E;
Hoe 140 = 10 nmol/l, Hoe). B Summary of
the data (eluate = 1 mg/ml; IC50 2.47 nmol/l).
FR = Fluorescence ratio.
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The FSGS Eluate Induced Increase of [Ca2+]i Is
Mediated via a B2 Kinin Receptor
Repeated application of bradykinin at a concentration
of 100 nmol/l led to a decline in the [Ca2+]i response of
podocytes. This effect could not be attributed to a deple-
tion of the internal Ca2+ stores, as the time interval
between the repeated applications of bradykinin in the
presence of 1 mmol/l Ca2+ in the bath solution allowed for
complete refilling of Ca2+ stores. Application of eluate
(1 mg/ml) following these repeated bradykinin pulses led
to a markedly diminished Ca2+ response of podocytes
(n = 5). The response to another IP3-elevating agent, the
purinoceptor agonist adenosine triphosphate (ATP;
100 Ìmol/l), was not affected. Figure 3 depicts an original
recording of the effect of eluate (1 mg/ml) before and after
repeated bradykinin (100 nmol/l) pulses.
The specific B2 kinin receptor antagonist Hoe 140 re-
versibly inhibited the eluate-induced elevation of [Ca2+]i
in a concentration-dependent manner. Figure 4A shows
an original recording of the effect of Hoe 140 (10 nmol/l)
on the eluate (1 mg/ml) induced Ca2+ transient; figure 4B
summarizes the data (IC50 2.47 nmol/l; n = 5 for each data
point). As blockade of bradykinin receptors by Hoe 140
completely abolished the Ca2+ response to eluate, the
Ca2+-liberating activity in eluate thus only was by kinin.
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Table 1. Free kinins in eluates derived by antibody-based IA
Incubation
period
min
2 mmol/l
EDTA
(+/–)
FSGS eluate
without
podocytes
n with
podocytes
n
Control eluate
without
podocytes
n with
podocytes
n
4 – 1,533B79 3 2,100B258 3 3,080B223 3 2,507B111 3
4 + 1,459a 2 1,459B179 3 3,710a 1 3,107B162 3
40 – 2,288B242 3 1,711B192 3 4,503B290 3 2,413B210 3
40 + 2,520B252 3 1,831B364 3 4,020B79 3 4,167B313 3
Eluates were dissolved in a Ringer-like solution with or without 2 mmol/l EDTA, followed by incubation for the
time periods indicated either with or without podocytes. Preparation of aliquots for kinin measurements was per-
formed as described in Subjects and Methods. Kinin was measured by RIA (mean B SEM; n = number of measure-
ments); the kinin concentration is given in picomoles per liter.
a Accidentally not performed in triplicate.
The concentration-response curve of the FSGS eluate
resembles that of bradykinin published recently by us [18]
for the same cell preparation used in the experiments
shown here. The Ca2+ increase induced by an eluate con-
centration of 0.2 mg/ml was approximately equivalent to
that due to 0.5 nmol/l bradykinin.
FSGS Eluate Does Not Elevate [Ca2+]i in Cells
Unreactive to Bradykinin
A human epithelial cell preparation derived from a
colon carcinoma (HT29) has been recently described not
to react to bradykinin by an increase of [Ca2+]i, even if
applied at unphysiologically high concentrations [28]. To
test for reactivity to eluate, additional microfluorescence
experiments were performed with this cell line. Neither
bradykinin (1 Ìmol/l) nor eluate (1 mg/ml) induced an
increase of [Ca2+]i. In contrast, the response to ATP
(10 Ìmol/l), which is known to increase [Ca2+]i in HT29
cells [28, 29], was not affected (n = 6, data not shown).
The Eluate-Induced Elevation of [Ca2+]i Is Caused by
Free Kinin
As the FSGS eluate induced [Ca2+]i increase could be
blocked by the specific B2 kinin receptor antagonist Hoe
140, it seemed likely that this effect was explained by free
kinins in the eluate preparation. Thus measurements of
kinins in different eluate preparations were performed.
We also studied whether kinin-releasing or kinin-degrad-
ing enzymes were present in the eluates or at the outer cell
membrane or were released from podocytes.
FSGS eluates derived by IA contained kinin in the
picomolar range (table 1). In most of the experiments ki-
nin concentrations were increased after a longer incuba-
tion period (40 vs. 4 min), indicating that a low kinino-
genase activity was present. Incubations in the presence of
EDTA (2 mmol/l), an inhibitor of kininases, did not cause
an alteration of the kinin concentration, demonstrating
the absence of active kininases. Thus, the [Ca2+]i increase
was obviously caused by the free kinin present in the
eluate preparations. No significant change of the kinin
concentration was observed during incubation of eluates
with podocytes.
Free Kinin in Eluate Derived by Antibody-Based IA Is
Not Specific for FSGS
To test for the specificity of kinin in the IA eluate for
FSGS, in a different series, eluate of a healthy volunteer
was used. This eluate was prepared exactly in the same
way as that of the FSGS patient. Control eluate increased
[Ca2+]i of podocytes in a fashion similar to that of FSGS
eluate. Figure 5 shows the respective concentration-
response curve (n = 3–8). As compared with the FSGS
eluate, the [Ca2+]i increase induced by control eluate at
the same concentration seemed more pronounced which
was also reflected in a certain shift of the concentration-
response curve (EC50 0.05 mg/ml; cf. fig. 5). The [Ca2+]i
increase induced by control eluate again could be revers-
ibly blocked by Hoe 140 (10 nmol/l; n = 5, data not
shown). Control eluates derived by IA contained kinin in
the picomolar range (table 1). As compared with the
FSGS eluate, the kinin levels in the control eluates were
increased. Like with FSGS eluates, the kinin concentra-
tions in the control eluates were increased after a longer
incubation period (40 vs. 4 min).
Eluate derived in the same way from a patient suffer-
ing from SLE with nephrotic proteinuria likewise elevated
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Fig. 5. Eluate from a healthy volunteer ele-
vates the [Ca2+]i of podocytes. Concentra-
tion-response curve (EC50 0.05 mg/ml). FR =
Fluorescence ratio.
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[Ca2+]i of podocytes (n = 5, data not shown). The respec-
tive [Ca2+]i increase could also be reversibly blocked by
Hoe 140 (10 nmol/l; n = 5, data not shown).
Discussion
In FSGS, IA either using a Sepharose-bound Staphylo-
coccus protein A [30] or a Sepharose-bound sheep antihu-
man immunoglobulin preparation [31] primarily aimed
at removing immunoglobulins. Despite of that, at present,
it seems unlikely that intact immunoglobulins are directly
causing the disease, as the approximate molecular weight
of the incriminated factor(s) was below 100 kD [5]. Based
on the specificity of IA for binding immunoglobulins,
Dantal et al. [32] hypothesized that immunoglobulins are
directly or indirectly involved in the mechanism leading
to proteinuria in FSGS patients. Whether immunoglobu-
lin fragments are involved, or proteins bound to immuno-
globulins, is not clear at present. Both IA procedures were
reported to result in the removal of the same putative
albuminuric factor which altered the glomerular albumin
permselectivity of purified glomeruli in vitro [32]. In con-
trast to studies showing the antiproteinuric effects of IA
procedures to be specific for FSGS, Esnault et al. [11]
demonstrated that IA also efficiently reduced proteinuria
caused by a number of other diseases: membranous
nephropathy, diabetes mellitus, IgA nephropathy, and
amyloidosis. Based on their data, they suggested that IA
removes a nonspecific circulating hemodynamics-altering
or permeability-increasing factor [11].
Podocytes are highly specialized cells which form the
outer part of the glomerular filtration barrier, contribut-
ing to its specific size and charge characteristics. With
regard to FSGS, an early injury of podocytes has been
assumed [33]. This led to the description of the initial
phase of FSGS in man as ‘podocytosis’ [34]. In the present
study, we investigated the Ca2+ response of cultured, dif-
ferentiated mouse podocytes to eluate derived by extra-
corporal antibody-based IA both from a patient with
recurrent FSGS and a healthy individual. Likewise, the
eluate from a patient with SLE suffering from nephrotic
syndrome owing to lupus nephritis in her renal transplant
was investigated. All three eluates markedly elevated the
[Ca2+]i level of podocytes. This Ca2+ increase was rapid
and reversible and consisted of an initial peak due to
release of Ca2+ from intracellular stores and a second pla-
teau-like phase due to influx of Ca2+ from the extracellular
space. The FSGS eluate induced Ca2+ increase was con-
centration dependent (EC50 0.14 mg/ml). A number of
observations provide evidence that this Ca2+ increase is
due to activation of B2 kinin receptors which are known to
be expressed on the surface of podocytes [35, 36]: (1) The
concentration-response curve of eluate resembles that of
bradykinin recently published by us for the same cell
preparation [18]. (2) Repeated application of bradykinin
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at a concentration of 100 nmol/l desensitized B2 kinin
receptors. The Ca2+ response to FSGS eluate following
these bradykinin pulses was markedly reduced. (3) The
specific B2 kinin antagonist Hoe 140 [37] reversibly inhib-
ited the eluate-induced elevation of [Ca2+]i. (4) Cells not
expressing B2 kinin receptors did not respond to eluate
with an increase of [Ca2+]i. Furthermore, kinins were
detected in the eluate preparation by radioimmunoassay.
As compared with the short half-life of kinins in the circu-
lation, due to degradation, e.g., by kininases, kinins in
eluate were stable and did not diminish over time. On the
contrary, the kinin concentrations increased by prolonged
incubation which may be attributed to an ongoing release
of kinins from high molecular weight precursors. In this
regard, the eluates used in this study contained relevant
amounts of (trypsin-)releasable kinins.
B2 kinin receptors have been described in numerous
tissues of different species [38]. Their activation among
other effects uniformly leads to an inositol phosphate
mediated increase of [Ca2+]i, which can be prevented by
the potent selective B2 kinin receptor antagonist Hoe 140
[37, 38]. Within this study, differentiated human podo-
cytes were not available. Therefore, experiments were
performed with differentiated mouse podocytes which
showed an arborized morphology and expression of the
podocyte markers WT-1 [15], synaptopodin [19], nephrin
[20], p57 [21], and CD2AP [22]. With B2 kinin receptors
already having been demonstrated in nondifferentiated
human podocytes [35, 36], we believe that similar results
are to be expected upon investigation of differentiated
human podocytes.
As antibody-based IA specifically removes immuno-
globulins from plasma, at first it is surprising that the
eluates under investigation contained significant amounts
of free kinin. The source of these kinins is not clear yet.
Kinins may be generated by the IA procedure itself; gener-
ation of bradykinin has been described in low-density
lipoprotein (LDL) adsorption due to use of the negatively
charged dextran sulfate cellulose [39] as well as in hemodi-
alysis with negatively charged dialyzer membranes such as
polyacrylonitrile, especially in combination with ACE
inhibitors [40]. Whether kinin is generated within the
setup used in this study, mainly consisting of a large-pore
plasmapheresis filter and Sepharose-containing IA col-
umns, is not known at present. Using a dextran sulfate
cellulose membrane for LDL apheresis, Murashima et al.
[39] demonstrated a marked depletion of high molecular
weight kininogen and prekallikrein on the one hand and
an increase of the bradykinin concentration on the other.
In addition, LDL apheresis has been described to decrease
proteinuria in patients with minimal change nephrotic
syndrome and membranous nephropathy [41]. Based on
these observations, Esnault et al. [11] suggested that the
hemodynamics-altering factor mentioned above could
possibly be removed both by IA and LDL apheresis [11].
With regard to proteinuria, the role of kinins has not
yet been fully elucidated. Inhibition of ACE (also known
as kininase II) does not only reduce angiotensin II, but
also decreases the breakdown, e.g., of bradykinin with
subsequent elevation of kinin levels. For this reason, it has
been a matter of debate whether the well-established anti-
proteinuric effect of ACE inhibition is due to a reduction
of intrarenal angiotensin II or to a decreased bradykinin
degeneration [42]. In vivo studies on this item provided
conflicting results; some found a significant contribution
of bradykinin to the antiproteinuric effect of ACE inhibi-
tors [43], others did not [42]. Concerning permeability
plasma factors, it appears questionable whether a single
unique mechanism leads to nephrotic proteinuria [10]. A
number of diverse factors may contribute to its patho-
physiology which could work as initiators, amplifiers, or
late effectors, as discussed by Esnault et al. [11]. In this
regard, the role of kinins awaits further clarification.
In summary, we have shown for the first time that
eluate derived by antibody-based IA contains high
amounts of free kinins, affecting cellular functions of podo-
cytes by activating B2 kinin receptors. As podocytes are the
primary target of injury in proteinuric diseases, here the
role of kinins deserves further investigation. It should be
noted, however, that raw eluate may contain a diversity of
biologically active substances. Hence, with regard to causal
implications for the pathogenesis of proteinuric diseases,
results directly obtained with eluate from IA procedures
should be interpreted with appropriate care.
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